The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the PI3K inhibitor BAY 80-6946 in hematologic malignancies.
Michael Jeffers
Employment or Leadership Position - Bayer
Ronald L. Dubowy
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Chetan D. Lathia
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Robert Mallon
Employment or Leadership Position - Bayer
Leonard Joseph Appleman
Research Funding - Bayer
Ramesh K. Ramanathan
Research Funding - Bayer
Amita Patnaik
Research Funding - Bayer